US Stock MarketDetailed Quotes
SCLX Scilex Holding
- 1.090
- -0.090-7.63%
Close Jun 7 16:00 ET
- 1.060
- -0.030-2.75%
Post 19:22 ET
197.50MMarket Cap-838P/E (TTM)
1.200High1.060Low1.01MVolume1.170Open1.180Pre Close1.13MTurnover0.85%Turnover RatioLossP/E (Static)181.19MShares8.30052wk High-1.04P/B129.17MFloat Cap0.73252wk Low--Dividend TTM118.50MShs Float16.900Historical High--Div YieldTTM11.86%Amplitude0.732Historical Low1.117Avg Price1Lot Size
Scilex Holding Stock Forum
Sign in to post a comment
$Scilex Holding(SCLX.US$ • The U.S. FDA approved the supplemental New Drug Application for Scilex Holdings' (NASDAQ:SCLX) Gloperba, a liquid, oral of colchicine for the prophylaxis of gout flares in adults.
• The company will launch the drug this month. It will cost $595 for a 150 mL bottle.
• Scilex noted that although colchine is currently available in a 0.6 mg tablet or capsule, many gout patients have chronic kidney disease or gastrointestinal sensitivity making a low...
• The company will launch the drug this month. It will cost $595 for a 150 mL bottle.
• Scilex noted that although colchine is currently available in a 0.6 mg tablet or capsule, many gout patients have chronic kidney disease or gastrointestinal sensitivity making a low...
8
$Scilex Holding(SCLX.US$ Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024
5
$Scilex Holding(SCLX.US$
Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024
Scilex Holding announced FDA approval for the commercial manufacturing of Gloperba®, the first and only liquid colchicine for gout prophylaxis. Launching in the U.S. on June 10, 2024, Gloperba® targets a growing market of 9.2 million gout sufferers. The U.S. gout treatmen...
Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024
Scilex Holding announced FDA approval for the commercial manufacturing of Gloperba®, the first and only liquid colchicine for gout prophylaxis. Launching in the U.S. on June 10, 2024, Gloperba® targets a growing market of 9.2 million gout sufferers. The U.S. gout treatmen...
1
1
$Scilex Holding(SCLX.US$
NEWS
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
NEWS
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
$Scilex Holding(SCLX.US$ cool thanks bro's, can i get some shares at 1.70 too? fick
2
$Scilex Holding (SCLX.US)$ looks like it's time for a reversal. See you on the way up 🚀
1
$Scilex Holding(SCLX.US$ finally found bottom watching for higher support still waiting
$Scilex Holding(SCLX.US$ Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
5
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Jaguar8 : Too expensive but definitely this should be covered by insurance
TrytosaveabitOP Jaguar8: Right! 600 bucks for 15 teaspoons? I believe I have that correct? Hehehe 10ml per TSP? Well Dr am I right.
Jaguar8 TrytosaveabitOP: Yes expensive. But when competitors come out with compatible formulation, this will drive down price. Or stick to oral colchicine . I forgot there is approx 20 tsps per 100ml
TrytosaveabitOP Jaguar8: Oh I thought it was 10ml per tsp!
Jaguar8 TrytosaveabitOP: It’s 5ml/tsp and 15ml/tbsp
View more comments...